Vyvanse Does Not Cause Cognitive Decline or Alzheimer's Disease
There is no evidence that Vyvanse (lisdexamfetamine) causes cognitive decline or increases the risk of Alzheimer's disease, even in individuals with a family history of Alzheimer's. The FDA-approved prescribing information for Vyvanse does not list cognitive decline or dementia as adverse effects, and the medication has been studied in patients with existing dementia without causing cognitive deterioration 1.
What the Evidence Shows
FDA Safety Profile
The official FDA labeling for Vyvanse extensively details potential adverse effects, including cardiovascular risks, psychiatric symptoms, and abuse potential, but nowhere mentions cognitive decline or increased dementia risk as a concern 1. The documented psychiatric side effects include new or worsening behavioral problems, psychotic symptoms, and manic symptoms—but not progressive cognitive impairment 1.
Use in Dementia Populations
Research has actually examined psychostimulants, including lisdexamfetamine, as potential treatments for symptoms in patients who already have dementia, particularly for apathy and excessive daytime sedation 2. While these studies found limited cognitive benefit, they did not demonstrate that stimulants cause cognitive decline or worsen dementia 2.
Recent Safety Meta-Analysis
A comprehensive 2025 meta-analysis of 93 randomized controlled trials examining stimulant safety across diverse patient populations—including patients with Alzheimer's disease—found an increased risk of general adverse events but did not identify cognitive decline or dementia progression as outcomes 3. The trials included participants with Alzheimer's disease, and cognitive deterioration was not reported as a safety concern 3.
Important Caveats About Stimulants in Older Adults
Medications to Avoid in Dementia
Guidelines on polypharmacy management in older adults specifically identify medications that do impair cognition, including anticholinergics (diphenhydramine, oxybutynin), benzodiazepines, antipsychotics, and opioids—but stimulants are not included in this list of cognitively impairing medications 4.
Appropriate Concerns About Stimulants
While Vyvanse does not cause Alzheimer's disease or cognitive decline, legitimate concerns in patients with cardiovascular risk factors or family history of dementia include:
- Cardiovascular effects: Increased blood pressure and heart rate, which require monitoring 1
- Psychiatric symptoms: Potential for anxiety, agitation, or psychosis (distinct from dementia) 1
- Sleep disruption: Which could indirectly affect cognitive function if severe 1
Clinical Bottom Line
If you or a family member with Alzheimer's risk factors requires Vyvanse for ADHD or binge eating disorder, the medication should not be avoided based on dementia concerns. The decision should focus on the established risks (cardiovascular, psychiatric, abuse potential) rather than unfounded fears about cognitive decline 1. Regular monitoring of blood pressure, heart rate, and mental status is appropriate, but this is standard practice for all patients on stimulants, not specific to those with Alzheimer's family history 1.